TABLE 5.

WGO Recommendations for the Management of Patients With Metabolic Dysfunction-associated Fatty Liver Disease in the COVID-19 Era

The identification and monitoring of patients with metabolic disease to identify MAFLD stage and grade is pivotal during and after the COVID-19 crisis Patients with MAFLD have a number of risk factors such as obesity diabetes mellitus which may translate to a higher mortality from respiratory illnesses, including COVID-19 Patients with MAFLD had a higher risk of respiratory disease progression than those without MAFLD Counseling of MAFLD patients to change lifestyle with a focus to curtail risk factors (such as obesity) that predict a poor prognosis of COVID-19 is encouraged

MAFLD indicates metabolic dysfunction-associated fatty liver disease; WGO, World Gastroenterology Organization.